CN102895352B - 药物组合物及其用途 - Google Patents
药物组合物及其用途 Download PDFInfo
- Publication number
- CN102895352B CN102895352B CN201210442956.8A CN201210442956A CN102895352B CN 102895352 B CN102895352 B CN 102895352B CN 201210442956 A CN201210442956 A CN 201210442956A CN 102895352 B CN102895352 B CN 102895352B
- Authority
- CN
- China
- Prior art keywords
- radix
- pharmaceutical composition
- blood
- rhizoma
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 43
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 31
- 208000006011 Stroke Diseases 0.000 claims description 30
- 239000002994 raw material Substances 0.000 claims description 20
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 206010019468 Hemiplegia Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 abstract description 51
- 239000008280 blood Substances 0.000 abstract description 38
- 210000004369 blood Anatomy 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 23
- 241000628997 Flos Species 0.000 abstract description 21
- 241001489978 Eupolyphaga Species 0.000 abstract description 19
- 230000001717 pathogenic effect Effects 0.000 abstract description 14
- 210000001835 viscera Anatomy 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000011084 recovery Methods 0.000 abstract description 5
- 241000258623 Whitmania pigra Species 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000001174 ascending effect Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 235000019633 pungent taste Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000010415 tropism Effects 0.000 abstract 1
- 241000237903 Hirudo Species 0.000 description 17
- 239000009636 Huang Qi Substances 0.000 description 17
- 241000208340 Araliaceae Species 0.000 description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 description 16
- 235000008434 ginseng Nutrition 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000010792 warming Methods 0.000 description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 10
- 241001604597 Pyrestini Species 0.000 description 10
- 241000522620 Scorpio Species 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 239000009490 scorpio Substances 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 241001643642 Viticis Species 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- 206010008132 Cerebral thrombosis Diseases 0.000 description 7
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 7
- 231100000862 numbness Toxicity 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 206010033799 Paralysis Diseases 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000000916 dilatatory effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000011800 void material Substances 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- -1 RONGSHUAN JIAONANG Substances 0.000 description 4
- 241001077909 Sigesbeckia Species 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009854 hydrometallurgy Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- MQBFFYQCZCKSBX-UHFFFAOYSA-N 5-hydroxy-6,7,8-trimethoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2OC3=C(OC)C(OC)=C(OC)C(O)=C3C(=O)C=2)=C1 MQBFFYQCZCKSBX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- ACVGWSKVRYFWRP-UHFFFAOYSA-N Rutecarpine Chemical compound C1=CC=C2C(=O)N(CCC=3C4=CC=CC=C4NC=33)C3=NC2=C1 ACVGWSKVRYFWRP-UHFFFAOYSA-N 0.000 description 2
- 208000008630 Sialorrhea Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-Pinoresinol Natural products C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- HGXBRUKMWQGOIE-NSMLZSOPSA-N (-)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-NSMLZSOPSA-N 0.000 description 1
- SQEBMLCQNJOCBG-HVHJFMEUSA-N (5s)-3-(hydroxymethyl)-5-methoxy-4-methyl-5-[(e)-2-phenylethenyl]furan-2-one Chemical compound C=1C=CC=CC=1/C=C/[C@]1(OC)OC(=O)C(CO)=C1C SQEBMLCQNJOCBG-HVHJFMEUSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- ICWHTQRTTHCUHW-IPYPFGDCSA-N 2-[(3s,5r,6r)-6,10-dimethylspiro[4.5]dec-9-en-3-yl]propan-2-ol Chemical compound C[C@@H]1CCC=C(C)[C@]11C[C@@H](C(C)(C)O)CC1 ICWHTQRTTHCUHW-IPYPFGDCSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- ICWHTQRTTHCUHW-UHFFFAOYSA-N Agarospirol Natural products CC1CCC=C(C)C11CC(C(C)(C)O)CC1 ICWHTQRTTHCUHW-UHFFFAOYSA-N 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 229930188400 Gardenin Natural products 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- BAHUBXAYVOCLNA-UHFFFAOYSA-N Isoangelol Natural products O1C(=O)C=CC2=C1C=C(OC)C(C(OC(=O)C(C)=CC)C(O)C(C)(C)O)=C2 BAHUBXAYVOCLNA-UHFFFAOYSA-N 0.000 description 1
- SQHQDXGIJPHZRZ-AAWDLAKASA-N Jujuboside A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@H](CC[C@@]2(C)[C@@]34C[C@]5([C@H]([C@@](C[C@@H](O5)C=C)(C)O)[C@H]4CC[C@H]42)OC3)[C@]4(C)CC1 SQHQDXGIJPHZRZ-AAWDLAKASA-N 0.000 description 1
- OAVAUZCEOWCYCC-BYHRGCEUSA-N Jujuboside B Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%10OC[C@@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@H]1O OAVAUZCEOWCYCC-BYHRGCEUSA-N 0.000 description 1
- CJJVPWAZSXVOOK-IGTKYRGASA-N Jujuboside B Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@H](CC[C@@]2(C)[C@@]34C[C@]5([C@H]([C@@](C[C@@H](O5)C=C)(C)O)[C@H]4CC[C@H]42)OC3)[C@]4(C)CC1 CJJVPWAZSXVOOK-IGTKYRGASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- BCPAKGGXGLGKIO-UHFFFAOYSA-N Pseudorutaecarpin Natural products C1=CC=C2C(=O)N(CCC3=C4C5=CC=CC=C5N3)C4=NC2=C1 BCPAKGGXGLGKIO-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OAVAUZCEOWCYCC-NZTCAOINSA-N Zizyphussaponin III Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%10OC[C@@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@@H]1O OAVAUZCEOWCYCC-NZTCAOINSA-N 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229930183733 angelol Natural products 0.000 description 1
- 201000000680 ankyloglossia Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000010225 buchang naoxintong Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- TVOFUERNMZTYRM-UHFFFAOYSA-N erythraline Natural products C1=C2C34CC(OC)C=CC3=CCN4CCC2=CC2=C1OCO2 TVOFUERNMZTYRM-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical class O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- DFNZYFAJQPLJFI-UHFFFAOYSA-N gentianine Chemical compound O=C1OCCC2=C1C=NC=C2C=C DFNZYFAJQPLJFI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000020245 homoiothermy Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- KVKRFLVYJLIZFD-OPGZLHQPSA-N jujuboside A Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%11OC[C@@H](O)[C@H](O)[C@H]%11O)[C@H](O)[C@H](O)[C@H]1O KVKRFLVYJLIZFD-OPGZLHQPSA-N 0.000 description 1
- QCLBRNPQMDEDIM-UHFFFAOYSA-N jujuboside C Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(O)COC1OC1C(C)(C)C(CCC2(C)C34CC5(C(C(CC(O5)C=C(C)C)(C)O)C4CCC42)OC3)C4(C)CC1 QCLBRNPQMDEDIM-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- JUTMAMXOAOYKHT-UHFFFAOYSA-N karrikinolide Natural products C1=COC=C2OC(=O)C(C)=C21 JUTMAMXOAOYKHT-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000009064 mailuoning Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- XFFOMNJIDRDDLQ-UHFFFAOYSA-N morusin Chemical compound O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XFFOMNJIDRDDLQ-UHFFFAOYSA-N 0.000 description 1
- WUBUWBUVAKMGCO-UHFFFAOYSA-N morusin Natural products CC(=CCC1=C(Cc2c3C=CC(C)(C)Oc3cc(O)c2C1=O)c4ccc(O)cc4O)C WUBUWBUVAKMGCO-UHFFFAOYSA-N 0.000 description 1
- XIWCDUHPYMOFIL-UHFFFAOYSA-N mulberrochromene Natural products O1C2=CC=3OC(C)(C)C=CC=3C(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XIWCDUHPYMOFIL-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000009561 tongxinluo Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种药物组合物,由包括以下份数的原料煎煮而成:桃仁20~35、红花15~30、土元18~24、水蛭8~15;以及该药物组合物的应用。本发明按五行规律,脏腑的相互关系,药物辛味归经,升降浮沉,致病的部位和各种致病的因素而综合组方,具有疗效快、疗期短、不复发、治病彻底、无毒副作用。采用本发明药物组合物治好的患者己达5000以上,治愈后多年已不再吃降血药和春冬输液,这就说明了本药的可靠性。
Description
技术领域
本发明涉及中药药物技术领域,尤其是在制备治疗中风和偏瘫疾病的药物的中药药物组合物。
背景技术
中风是由于脑部供血液受阻而迅速发展的脑功能损失,可因血栓或栓塞所造成的缺血(缺乏血液供应),或因出血。世界卫生组织在20世纪70年代给出的中风的传统定义是“24小时以上脑神经功能缺损,或在24小时内死亡”。这个24小时的定义是用来区别短暂性脑缺血(可在24小时内完全康复)。因为中风如果早期治疗,可以减少中风的后遗症,许多人现在宁愿用其他代概念,如脑攻击和急性缺血性脑综合症(模仿心脏病发作和急性冠脉综合征),反映中风需要迅速采取行动的迫切性。
在过去,中风被称为脑血管意外或CVA,但现在通用“中风”。中风属于急症,可造成永久性神经损害,如果不及时诊断和治疗可造成并发症和死亡。在美国,中风是第三大死因,在美国和欧洲它是导致成人残疾的首因。在世界各地中风是第二大死因。中风的危险因素包括高龄,高血压,前中风史或短暂性脑缺血发作(TIA),糖尿病,高胆固醇,抽烟,心房颤动。高血压是中风最重要的危险因素变量。
目前中风治疗治疗效果是现在各大医院按常规治法,根本无法完成,在全国各大小医院都是按常规治疗,如高血压、脑血栓、血脂稠、中风偏瘫等心脑血管病、常用药物,北京降血灵、复方丹参滴丸、偏瘫复原丸、地奥心血康、步长脑心通、通心络、溶栓胶囊、脉络宁等都是降血压为主,辨证不全面,所在患者天天吃药,每年冬、春输液只能起到缓解作用,虽长期用药脏腑功能下降,却疗效无几,根本达不到彻底治疗的效果。
发明内容
本发明针对不足,提出一种药物组合物,能用于制备治疗中风和偏瘫疾病的药物,具有很好的疗效,疗效快、疗期短、不复发、治病彻底、无毒副作用。
为了实现上述发明目的,本发明提供以下技术方案:一种药物组合物,由包括以下份数的原料煎煮而成:
桃仁 20~35 红花 15~30
土元 18~24 水蛭 8~15。
优选的,还包括以下份数的原料:
优选的,还包括以下份数的原料:
优选的,还包括以下份数的原料:
本发明药物组合物的制备方法为传统的煎煮法,即水提法,温度80度~100度,提液三次,每次二小时。
本发明还提供以下技术方案:上述药物组合物在制备治疗中风和偏瘫疾病的药物中的应用。
应用依据:1、中风是由于气血逆乱,导致脑脉痹阻,或血溢于脑,以昏迷仆倒,半身不遂,肢麻舌蹇等为主要临床表现一种疾病,相当于现代医学的脑血管病。
2、(金匾要略浅注補正卷二)明确指出中风大纲,风从虚入,(指阳虚而言),热从风发,内热外风,挟寒、挟湿、虚寒相博、紧脉为寒、浮脉为虚、明确指明了心脑血管疾病复杂致病的因素,寒虚相博,络脉空虚,正气引邪,嘴歪眼斜,邪在于络,肌肤不仁,邪在于经,筋骨重滞足手不运,邪在于府,即不识人事,邪在于脏,心肾二脏俱连舌体,脏气厥,而不至舌下,舌即难言,口必吐涎,风邪在皮肤、肌肉之间,气滞血癖,正气不达,痰湿阻络,肌肉死不知疼痒,为肌肤麻木不仁,邪入于胃,胃脉上通于心,邪气生痰聚血,上迷心窍,血乱于心中,则魄死神迷,气化津液气聚于空窍,则津结为涎,舌下气不收摄,故口吐涎,厥阴肝经,少阴肾经,二经其中有相火,被阴寒之邪挌拒以外,形成阴盛挌阳故头疼,太阳经、阳明经,两经表感受风寒所致故项强。心阳不足,肾寒水上逆,心失所养,故心悸,肝气郁结,肝肾阳虚,脾不健运,痰湿中阻,髓海不充,故眩晕。
以上所描述中风致病特点,不难看出成病的根本原因为“虚寒症”。
下面对各种原料的药理分别陈述如下:
1)桃仁:桃仁含苦杏仁甙挥发油、脂肪油苦杏仁酶等。桃仁醇提取物有抗血凝、溶血作用。
2)红花:红花含二氨黄酮衍生物,红花甙、红花醌甙脂肪油,全身有扩张血管作用,增加心冠脉流量、抗凝血。
3)土元:破血逐瘀、活血通经。
4)水蛭:水蛭素、含肝素、抗血素等。
5)人参:人参含13种以上的皂甙多种氨基酸。人参可使高血压患恢复正常,改善机体免疫功能,均有溶血作用。
6)黄芪:黄芪含有铬、锰、铁、钴、铜、锌、硒、铝等14种微量元素。黄芪有强心及保护缺血心肌的作用,有增强免疫功能有降血作用。
7)当归:当归含挥发油,主要成份藁本内脂、含有钾、钠、钙、镁、硅。当归有增加心肌血液供给,增加循环血流量,抗心律失常,抗血栓。
8)熟地:养血滋阴,补精益髓。
9)白术:白术挥发油主要成份苍术醇、苍木酮、茅术醇、白术内酯甲和乙等,白术具有补气健脾,扩张血管、利尿作用。
10)巴戟天:本品含维生素C、糖类植物甾醇及微量蒽醌等。巴戟天具有补肾助阳、祛风除湿。
11)杜仲:本品含松脂醇二葡萄糖甙。杜仲具有补肝肾强筋骨,扩张血管,降血压等作用。
12)丹参:本品含丹参酮、丹参酚、原儿茶醛、原儿茶酸、维生素E,丹参具有扩张冠动脉、增加冠动脉血流量,调整心律作用。
13)山芋肉:本品含山茱萸甙蕃木鳖甙、皂甙没食手酸、苯果酸、维生素A。本品补益肝肾,收敛固涩,利尿降压作用。
14)酸枣仁:本品含皂甙,酸枣仁皂甙A及B。本品具有补肝宁心、敛汗生津、镇静、降血作用。
15)菟丝子;菟丝子含树脂甙、糖类。本品有补阳益阴固精缩尿,增强心脏收缩力。
16)吴茱萸:本品含挥发油:主要为:吴茱萸烯、罗勒烯、吴茱萸内酯等。本品挥发油有芳香健胃作用,吴茱萸硷及吴茱萸内酯有镇痛作用。
17)茯苓:本品主要含茯苓聚糖、茯苓醇。本品健脾安神、利尿。
18)细辛:本产品细辛油有明显的抗惊厥、镇痛、解热、散寒解表温肺化饮作用;
19)白芷:白芷含多种香豆精类化合物、比克一白芷素。比克一白芷素对冠状血管有扩张作用,能解、祛风燥湿。
20)天麻;含天麻素。平肝息风、明显降低外围血管和冠状血管阻力增加血流量。
21)全蝎:是一种类似蛇毒神经毒的蛋白质。本品息风止痉、通络止痛。
22)豨莶草:本品含多种二萜类化合物。祛风湿、通经络有降压作用。
23)蔓荆子:本品挥发油具有增加心肌营养性血流量作用,疏通散寒,清利头目。
24)防风:含挥发油,甘露醇、酚类、多糖、有机酸、苦味甙;祛风解表、胜湿、止痛、解痉。
25)独活:独活内酷(当归醇)本品祛风湿、止痛、解痉。
26)羌活:本品含榭皮素一甲醚,树脂及草柔质。解表散寒、祛风胜湿、止痛。
27)川芎:本品含挥发油,生物碱、酚生物碱等。直接扩张周围血管使冠状动脉血流量和下肢血流量增加降低血压。
28)海桐皮:含生物碱刺桐灵碱氨基酸,有机酸。本品祛风湿、通经络。
29)麻黄:主要含麻黄碱。麻黄碱主要作用为松驰支气管平滑肌、发汗、平喘、利尿。
30)川断:本品含龙胆碱、三菇皂甙;补肝肾、行血脉、续筋骨。
31)桑枝:本品含桑素、桑色素、桑色烯、蔗糖、葡萄糖。祛风通络、利关节、通血脉。
32)黑附子:本品含乌头碱。增加股动脉血流量,回阳救逆,温肾助阳,祛寒祛痛。
33)肉桂:本品主要含桂皮醛、桂皮酸。补火助阳、散寒止痛、温经通脉并能解除内脏平滑肌痉挛。
34)黄连:本品含主要成分黄连素,清热燥湿、泻火解毒。
35)黄芩:本品含黄芩甙、黄芩黄素、汉黄芩甙、汉黄芩素等。解热镇静、降压、利胆、利尿。
36)草决明:降血压。
37)大黄:大黄具有利尿、保肝和降胆固醇作用,清热泻火、活血化痪。
38)栀子:含栀子素,泻火除烦,利胆、降血压。
39)薄荷:清头目,透疹。
40)芒硝:芒硝主含硫酸钠,泻下、软坚、清热。
41)石膏:主要为含水硫酸钙,清热泻火、除烦止渴。
42)滑石:主要含硅酸镁,利水通淋、清血分之湿热。
因此,本发明药物组合物的功能:扩张血管,增加血流量,抗凝血、溶血、稳血压、大补元气,扶正固脱。可用于中风引起的高血压、脑血栓、中风后遗症、肢体麻木、口眼歪斜、血脂稠、眩晕症、心悸、水肿等症状的药物制备。
本发明药物组合物可按照传统药物制剂形式制成各种剂型,本发明以其胶囊为例进行说明,含量:每粒胶囊中含药物组合物为0.5克(30天为一疗程);
用法与用量:每日三次,早上饭前5粒,中午饭前5粒。晚睡觉前5粒,温开水送下;为单药治病,不需与任何中西药配伍同服。
适应人群:中老年人。禁忌:孕妇、各种酒类、各种冷饮、生冷食物、湿热病人。
本发明药物组合物中,按照中药方剂配伍组成原则:
1、君药:桃仁、红花、土元、水蛭;
2、臣药:人参、黄芪、当归、熟地、白术、巴戟天、杜仲、丹参、山萸肉、酸枣仁、菟丝子、吴茱萸;
3、佐药:茯苓、细辛、白芷、天麻、全蝎、豨莶草、蔓荆子、防风、独活、羌活、川芎、海桐皮、麻黄、川断、桑枝、黑附子、肉桂;
4、使药:黄连、黄芩、草决明、大黄、栀子、薄荷、芒硝、石膏、滑石。
辨证施治简述:
⑴高血压:七情内伤、肝肾受阴寒之邪,阳气不足,气滞血瘀。气虚血凉,故头晕、头痛、恶心、身体笨重。
治则:本方中巴戟天、杜仲、芋肉,温肝助阳;吴茱萸、白术,温胃健脾;天麻、羌活、川芎、白芷,祛头风;黑附子、肉桂,引火归原;草决明、豨莶草、丹参,可降压。
⑵脑血栓:脏腑阴阳失调,头为百风之会,脏腑阳气不足,风从虚入,气阻血、血寒凝而血栓。
治则:桃仁、红花、土元、水蛭,抗凝血溶血;黑附子、肉桂、细辛、吴茱萸,助阳温血祛寒;天麻、白芷、全蝎、川芎,祛头风而解痉;防风、独活、羌活,海桐皮,均有祛风湿、通经络作用;人参、黄芪、当归、熟地、白术,大补元气使血见温则行,脉管营气充足血不淤滞。
⑶肢体麻木不仁:风邪在皮肤肌肉之间、气滞不足,肌肉死血,不知疼痒,为肌肤麻木不仁。
治则:方中麻黄、防丰、独活、羌活,可宣肺解表祛寒气;海桐皮、桑枝、豨莶草,祛寒祛湿、通筋活络;川断、杜仲、黑附子、肉桂,温里壮阳;水蛭、桃仁、红花、土元,活血化瘀;人参、黄芪、白术、熟地、当归,大补气血。
⑷口眼歪斜:寒虚相博、气血俱虚,风邪乘虚而入中经络脉络因寒收引。
治则:麻黄、独活、羌活、细辛,可辛温解表祛内寒;白芷、全蝎、天麻,可息风解痉;黑附子、肉桂、黄芪、熟地,温补气血。
⑸血脂稠:肝肾虚寒、膀胱虚寒小便清长而下流,水分不能入血,而形成脏燥而血绛使血液粘稠。
治则:黑附子、肉桂、细辛、杜仲、川断、巴戟天,补肝阳、肾阳、温补命门之火,温膀胱,使水分入血稀血;少佐黄连、黄芩、栀子、薄荷、滑石、石膏,清脏燥和血分之虚热。
⑹眩晕症:肝气郁结,下焦肝肾虚寒、脾寒不运健痰湿中阻,清阳不升,髓海不足而眩晕。
治则:桃仁、红花、土元,归肝经可活血理肝解郁;白术、吴茱萸、白芷,起到温脾健脾作用;川断、杜仲、细辛、黑附子,均有壮阳祛寒、补纳肾气;天麻、蔓荆子、川芎,各有祛痰、祛风、清阳作用;人参、当归、黄芪、熟地、菟丝子,均有补阴补阳、补气补血益精填髓的作用。
⑺心悸:心阳不足,心失所养。
治则:方中丹参、酸枣仁,可补心养心;黑附子、细辛,可温肾治寒水上逆。
⑻水肿:水肿分为阴水、阳水二种风邪入脏、阳水脏腑阳气不足,不能温化水湿、水湿内停而水肿。
治则:补纳脏腑阳气,方中黑附子、肉桂,温肾壮阳;麻黄、细辛、羌活,可宣肺散寒;吴茱萸、白术、茯苓,温胃健脾。
以上陈述更说明中风之病并不是一脏一腑单一致病,脏腑的相乘相克是连贯的,所以在治则上药物,配方上应该综合考虑,才能达到全面彻底的治疗效果。
治愈标准:
中风偏瘫后遗症服本药6个月至l年可痊愈,高血压,服本药3~4个月,血脂稠服本药3~4个月,就能达到彻底治愈,治好后一切体诊正常,不复发,不需日常天天再用各种中西药维持,和冬季春季输液预防,彻底杜绝了终身吃药的传统疗法。
与现有技术相比,本发明按五行规律,脏腑的相互关系,药物辛味归经,升降浮沉,致病的部位和各种致病的因素而综合组方,具有疗效快、疗期短、不复发、治病彻底、无毒副作用。采用本发明药物组合物治好的患者己达5000以上,治愈后多年已不再吃降血药和春冬输液,这就说明了本药的可靠性。
具体实施方式
下面结合具体实施例对本发明进行详细描述,本部分的描述仅是示范性和解释性,不应对本发明的保护范围有任何的限制作用。
实施例1
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁20、红花30、土元18、水蛭15。
实施例2
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁35、红花15、土元24、水蛭8。
实施例3
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁30、红花20、土元20、水蛭10。
实施例4
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁20、红花30、土元18、水蛭15、人参18、黄芪35、当归18、熟地35、白术16、巴戟天23、杜仲19、丹参21、山芋肉19、酸枣仁21、菟丝子19、吴茱萸13。
实施例5
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁35、红花15、土元24、水蛭8、人参24、黄芪20、当归24、熟地25、白术24、巴戟天17、杜仲21、丹参19、山芋肉21、酸枣仁19、菟丝子21、吴茱萸7。
实施例6
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁30、红花20、土元20、水蛭10、人参20、黄芪30、当归20、熟地30、白术20、巴戟天20、杜仲20、丹参20、山芋肉20、酸枣仁20、菟丝子20、吴茱萸10。
实施例7
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁35、红花15、土元24、水蛭8、人参24、黄芪20、当归24、熟地25、白术24、巴戟天17、杜仲21、丹参19、山芋肉21、酸枣仁19、菟丝子21、吴茱萸7、茯苓22、细辛6、白芷22、天麻17、全蝎14、豨莶草17、蔓荆子22、防风17、独活22、羌活17、川芎22、海桐皮26、麻黄14、川断26、桑叶22、黑附子12、肉桂14。
实施例8
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁20、红花30、土元18、水蛭15、人参18、黄芪35、当归18、熟地35、白术16、巴戟天23、杜仲19、丹参21、山芋肉19、酸枣仁21、菟丝子19、吴茱萸13、茯苓17、细辛14、白芷17、天麻22、全蝎6、豨莶草22、蔓荆子17、防风22、独活17、羌活22、川芎17、海桐皮33、麻黄6、川断33、桑叶17、黑附子18、肉桂6。
实施例9
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁30、红花20、土元20、水蛭10、人参20、黄芪30、当归20、熟地30、白术20、巴戟天20、杜仲20、丹参20、山芋肉20、酸枣仁20、菟丝子20、吴茱萸10、茯苓20、细辛10、白芷20、天麻20、全蝎10、豨莶草20、蔓荆子20、防风20、独活20、羌活20、川芎20、海桐皮30、麻黄10、川断30、桑叶20、黑附子15、肉桂10。
实施例10
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁30、红花20、土元20、水蛭10、人参20、黄芪30、当归20、熟地30、白术20、巴戟天20、杜仲20、丹参20、山芋肉20、酸枣仁20、菟丝子20、吴茱萸10、茯苓20、细辛10、白芷20、天麻20、全蝎10、豨莶草20、蔓荆子20、防风20、独活20、羌活20、川芎20、海桐皮30、麻黄10、川断30、桑叶20、黑附子15、肉桂10、黄连10、黄芩15、草决明20、大黄15、栀子10、薄荷10、芒硝10、石膏30、滑石30。
实施例11
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁35、红花15、土元24、水蛭8、人参24、黄芪20、当归24、熟地25、白术24、巴戟天17、杜仲21、丹参19、山芋肉21、酸枣仁19、菟丝子21、吴茱萸7、茯苓22、细辛6、白芷22、天麻17、全蝎14、豨莶草17、蔓荆子22、防风17、独活22、羌活17、川芎22、海桐皮26、麻黄14、川断26、桑叶22、黑附子12、肉桂14、黄连6、黄芩18、草决明17、大黄18、栀子6、薄荷14、芒硝6、石膏33、滑石26。
实施例12
一种药物组合物,由包括以下份数的原料煎煮而成:桃仁20、红花30、土元18、水蛭15、人参18、黄芪35、当归18、熟地35、白术16、巴戟天23、杜仲19、丹参21、山芋肉19、酸枣仁21、菟丝子19、吴茱萸13、茯苓17、细辛14、白芷17、天麻22、全蝎6、豨莶草22、蔓荆子17、防风22、独活17、羌活22、川芎17、海桐皮33、麻黄6、川断33、桑叶17、黑附子18、肉桂6、黄连14、黄芩12、草决明22、大黄12、栀子14、薄荷6、芒硝14、石膏26、滑石33。
上述所有实施例产品的制备工艺均如下所述:
1、药品筛选:去除灰尘、杂质、次品;
2、提液法:水蒸气式水提法,温度80度~100度,提液三次,每次二小时。
3、烘干:温度80度~100度。
4、灭菌法:灭菌消毒柜。
5、制剂:按传统制剂制作工艺,将产品制成各种剂型。
临床具体试验例
1.某女,45岁,安阳县水冶镇阜城东街人,患脑血栓,口歪眼斜,不能说话,右侧偏瘫,无任何知觉,住院一个月不见好转,出院后服实施例1药物胶囊6天见效,连服6个月(早5粒、中午5粒、晚5粒,只用单药,不和任何西药配伍)体症恢复正常无任何后遗症,治愈后什么药也无用过,也没复发过,好后在铁厂上班至今五年。
2.某男,62岁,汤阴县小光村人,脑中风后遗症卧床不起,全身浮肿,神智昏迷,血压不正常,二年住院三次,病情十分危急,服实施例3片剂十五天效果特别明显,连服8个月痊愈,现自己一切生活处理,至今三年不吃药维持没复发。
3.某女,56岁,东姚镇辛村人,多年高血压、血脂稠,经常眩晕,住过二次医院治疗,不能根治反复发作。服用实施例5丸剂3个月症状全部消除,4年来从无复发过。
4.某女,45岁,安阳县水冶镇阜城东街村人。患脑血栓,口歪眼斜,不能说话,右侧偏瘫,无任何知觉,住院治疗一个月不见好转,出院后服实施例7汤剂6天见效,连服6个月体诊一切恢复正常,无任何后遗症,好后在铁厂上班至今六年,什么药也没用过。
5.某男,50岁,林州市辛村人,脑出血后遗症,右半身偏瘫,神志不清,口歪眼斜,流口水,不会说话,一年住院两次,出院回家后,二年卧床不能动,身体水肿,手足不能动,像植物人一样。二年后才开始服用实施例8胶囊,日服三次,每次5粒,连服8个月痊愈,不用任何药物配合,现在外搞建筑和正常人一样,至今五年。
6.某男,68岁,林州市百文村人,脑血栓后遗症,半身不遂,生活不能自理,二年复发三次住院,常规治疗不见好转,家人失去信心,后经人介绍服用实施例9胶囊6个月(日三次,每次5粒,单药治病)现生活工作一切正常,体诊正常至今5年。
7.某男,48岁,林州市东岗村人,脑溢血后遗症,一年住院二次,出院后卧床不起,神智昏迷、不知人事,大小便失禁,不能说话,全身肤色暗紫而水肿,后经人介绍服实施例10胶囊8个月,以前症状全部消失,体诊正常,上班至今四年(日常从无服任何中西药维持)。
8.某男,61岁,汤阴县城人,脑血栓,右侧偏瘫,手足无知觉,口歪眼斜,流口水,不能下床,大小便失禁,身体水肿,二年住院两次靠家人护理,效果无明显改善,后改服实施例11胶囊6个月,经医院检查,体症已恢复正常,现行走自如,生活自理。
9.某男,50岁,安阳县水冶镇阜城西街人,脑血栓,右侧偏瘫,手足无知觉,住院十五天花费1万5仟元,症状无明显改善,出院后,服实施例12胶囊3个月,一切症状得到治愈,至今五年从无复发过,也不用输液、吃药维护,一切生活正常。
上述每个具体临床案例所用的药物组合物,治愈的案例都有上百件甚至数百件,以上临床试验只是从5000以上已治愈的患者中挑选出的代表性案例。
总之,高血压、血脂稠、脑溢血后遗症、脑血栓后遗症、中风后遗症等,它的病因基本相同,虽说男女不同、年龄不同,但都是五脏六胕功能的相互关系失调,导致疾病的发生,所以在治则上必须全面注意治病药物的性能归经,才能同时起到标本整体治疗作用。
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210442956.8A CN102895352B (zh) | 2012-11-07 | 2012-11-07 | 药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210442956.8A CN102895352B (zh) | 2012-11-07 | 2012-11-07 | 药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102895352A CN102895352A (zh) | 2013-01-30 |
CN102895352B true CN102895352B (zh) | 2014-03-26 |
Family
ID=47568038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210442956.8A Expired - Fee Related CN102895352B (zh) | 2012-11-07 | 2012-11-07 | 药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102895352B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116036186B (zh) * | 2022-11-24 | 2024-02-13 | 湖南惜品医疗科技有限公司 | 消栓贴、制备方法及其在治疗静脉血栓栓塞症中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091972A (zh) * | 1993-10-23 | 1994-09-14 | 薛维著 | 中风酊霜 |
CN1101692C (zh) * | 2000-09-26 | 2003-02-19 | 袁曙光 | 治疗中风偏瘫的中药配制方法 |
CN100350928C (zh) * | 2005-05-30 | 2007-11-28 | 浙江海正药业股份有限公司 | 一种治疗脑中风的脑血栓泡腾片及其制备方法 |
CN100457171C (zh) * | 2005-06-10 | 2009-02-04 | 崔赤锋 | 一种治疗中风偏瘫病药物的制备方法 |
CN101721664A (zh) * | 2008-11-04 | 2010-06-09 | 王生 | 一种治疗中风偏瘫及全身瘫痪的中药 |
CN102139065A (zh) * | 2011-03-30 | 2011-08-03 | 宋瑞丰 | 一种用中草药制作的治疗心脑血管疾病的胶囊 |
-
2012
- 2012-11-07 CN CN201210442956.8A patent/CN102895352B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102895352A (zh) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1209121C (zh) | 一种治疗心脏病的强心通脉液及其制备方法 | |
CN103656238B (zh) | 一种治疗风湿骨病的中药组合物 | |
CN102698137B (zh) | 一种具有降低血压作用的组合物及其制备方法 | |
CN101991816A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN103432393B (zh) | 一种治疗高血压的中药组合物 | |
CN101524469B (zh) | 一种治疗充血性心力衰竭的中药复方制剂及其制备方法 | |
CN104689226A (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN103520366B (zh) | 用于治疗中风后痉挛性偏瘫的中药 | |
CN104815192A (zh) | 一种治疗高血压的药物组合物及其应用 | |
CN103182012A (zh) | 一种治疗缺血性脑中风的药物及其制备方法 | |
CN105343466A (zh) | 一种治疗冠心病的中药组合物 | |
CN105561002A (zh) | 一种艾叶保健足浴粉及其制备方法 | |
CN102406799A (zh) | 治疗糖尿病高血压并发冠心病的巴布膏及其制备方法 | |
CN102526581B (zh) | 一种用于治疗高血压疾病的中药组合物 | |
CN102895352B (zh) | 药物组合物及其用途 | |
CN101244117B (zh) | 一种治疗痔疮的中成药剂及其制作方法 | |
CN106938048A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN105343688A (zh) | 一种治疗心肌梗塞的药物组合物及其应用 | |
CN104922499A (zh) | 一种治疗肝炎的中药 | |
CN104906502A (zh) | 一种用于治疗鸡伤热的药物组合物及其制备方法 | |
CN104367896B (zh) | 一种治疗气虚血瘀型中风的药物组合物及其制备方法 | |
CN110464803A (zh) | 一种用于降低血压的中药组合物及其制备方法 | |
CN101797351B (zh) | 防治老年痴呆的中药 | |
CN106139111A (zh) | 一种可有效治疗抑郁症的中药组合物及其制备方法 | |
CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140326 |
|
CF01 | Termination of patent right due to non-payment of annual fee |